Serum Phospholipases A2 in Patients Undergoing Panproctocolectomy Because of Severe Ulcerative Colitis by Haapamäki, Markku M. et al.
Eur J Clin Chem din Biochem 1997; 35(10):749-754 © 1997 by Walter de Gruyter · Berlin · New York
Serum Phospholipases AI in Patients Undergoing Panproctocolectomy
Because of Severe Ulcerative Colitis1)
Markku M. Haapam ki1, Juha M. Gr nroos1, Erkki Pekkala1, Anne Jokilammi-Siltanen2, Kerttu Irjala3,
Kalle Lertola4 and Timo J. Nevalainen2
1
 Department of Surgery, University of Turku, Turku, Finland
2
 Department of Pathology, University of Turku, Turku, Finland
3
 Central Laboratory, Turku University Central Hospital, Turku, Finland
4
 Department of Statistics, University of Turku, Turku, Finland
Summary: A major role has been proposed for group II phospholipase A2 in the pathogenesis of local and general-
ised inflammatory reactions. Elevated catalytic activity and mass concentrations of this enzyme have been found
in serum and tissue samples of the colon in patients with active ulcerative colitis. The cellular source(s) of group
II phospholipase Az in the blood circulation is (are) unknown. In the current prospective study, we investigated the
mass concentration of group II phospholipase AI and the catalytic activity concentration of phospholipase AI in
serial serum samples of 15 consecutive patients who underwent a standard panproctocolectomy operation for severe
ulcerative colitis. Both the catalytic activity concentrations of phospholipase A2 and the mass concentrations of
group II phospholipase AI increased rapidly in serum samples to maximum values on the first postoperative day
and then decreased (p = 0.002 and p < 0.001, respectively) in patients who recovered uneventfully. Three patients
had postoperative complications that further increased the enzyme concentrations at the time of respective complica-
tions. The pattern of group II phospholipase Az mass concentration profiles was similar to the profiles of C-reactive
protein. The results show that the removal of the large bowel does not eliminate the potential to secrete group II
phospholipase AZ into the blood circulation in these patients. Secretion of group II phospholipase A2 into the
circulation after surgery seems to be a normal host response to a major abdominal operation and postoperative
complications. Consequently, we conclude that the large bowel is not an important source of group II phospholipase
AZ in sera of patients with ulcerative colitis. The results also support the assumptions that the catalytic activity of
phospholipase A2 in serum is attributable to group II phospholipase A2 and that this enzyme is an acute phase pro-
tein.
Introduction phospholipase Az originates from pancreatic acinar cells
Phospholipase A22) hydrolyses the fatty acyl ester bond and serves mai^ as a diSestive enz>rme· GrouP Π Phos'
at the sn-2 position of glycerophospholipids. The en- PholiPase Az is found ώ several cells and tissues such
zyme is widespread in bacteria, plants, snake and bee as articular cartilaSe <6' 7>' Paneth cells of the smal1
venoms, mammalian cells, and secretions (1, 2). Phos- intestinal mucosa <8' 9>' the amnionic ePithelial cells of
pholipase A2 has been implicated in the pathology of fetal membranes (10) and the gland cells of the Prostate
•
 α . ,- · Λ A· · f <-· (11) or extracellularly when released in response to pro-various inflammatory diseases including infections, sep- v ' J v r
. , . . . , „ , , ,. , , ,. inflammatory mediators such as mterleukin-1, interleu-
sis, various arthntides, Crohns disease and ulcerative J '
,..·
 (^ kin-6 or tumour necrosis factor (12, 13). The mass con-
centration of group II phospholipase A2 and catalytic
Secretory phospholipases A2 are divided into several activity concentration of phospholipase A2 are notably
groups on the basis of the amino acid sequence of the increased in sera of patients with inflammatory diseases
enzyme (4, 5). Group I and II phospholipases A2 are (14) including inflammatory bowel diseases (15). A ma-
present in human tissues, have high disulphide bond jor role has been proposed for group II phospholipase
content, low molecular mass (14000 Mr) and require A2 in the pathogenesis of local and generalised inflam-
millimolar concentrations of Ca2+ for catalysis. Group I
 matory reactions. The cellular source(s) of group II
- phospholipase A2 found in the circulation is (are) un-
') Supported by the Instrumentarium Scientific Fund, the Cancer known. We have recently shown group II phospholipase
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Phospholipase A2, phosphatide 2-acylhydrolase (EC 3.1.1.4) the mucosa of inflamed large intestine in ulcerative coli-
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tis (9). Against this background, the inflamed colon
might be a source of circulating group II phospholipase
A2 in patients with active drug-resistant ulcerative coli-
tis, as suggested in a recent report (16).
The purpose of the present work was to study the effect
of panproctocolectomy on the catalytic activity concen-
tration of phospholipase A2 and the mass concentration
of group II phospholipase A2 in serum in ulcerative coli-
tis. The mass concentration of group I phospholipase A2
was measured to rule out pancreatic involvement in a
possible postoperative increase in the catalytic activities
of phospholipase A2. The mass concentration of C-re-
active protein was measured to detect postoperative
complications and also for comparison between this
classic acute phase reactant and the phospholipase A2
measurements. The results show that panproctocolec-
tomy does not result in the disappearance of group II
phospholipase A2 from serum of patients with ulcera-
tive colitis.
Materials and Methods
Patients
Fifteen consecutive patients operated for ulcerative colitis at the
University Central Hospital of Turku were enrolled in the present
prospective study. There were nine men and six women; the mean
age of the patients was 40 years (range 22 to 70 years). The average
length of the disease history was 10 years and six months (range
10 months to 28 years). All patients were operated for active and
drug resistant ulcerative colitis and one patient had dysplastic
changes in the colonic mucosa before the operation. Thirteen pa-
tients received oral prednisone (range 5 to 80 mg/day) preopera-
tively and these patients were given intravenous hydrocortisone
(range 100 to 200 mg/day) or methylprednisolone (range 80 to
125 mg/day) during the recovery period. The corticosteroid doses
were gradually decreased to preoperative levels and oral medica-
tion was started on the 5th to 14th postoperative day depending on
the patient's general condition and bowel function. The corticoste-
roid therapy was discontinued one to three months after the opera-
tion. Nine patients received 5-aminosalicylic acid (range 1200 to
3600 mg/day), five patients received salazosulphapyridine (range
3000 to 4500 mg/day) and three patients received antibiotics before
the operation. All patients received systemic prophylactic therapy
with cefuroxim (2250 mg/day) and metronidazole (1500 mg/day)
during five postoperative days. Two men and one woman were
excluded from the statistical analysis due to complications during
the recovery period, since we assume that early complications may
affect the measurements of interest. One of the excluded men had
a short period of acute respiratory insufficiency on the third postop-
erative day and was treated in the intensive care unit, and the other
man had pneumonia diagnosed on the seventh postoperative day.
The female patient excluded had a postoperative intestinal obstruc-
tion and was reoperated on the seventh day after the panproctoco-
lectomy. Eleven of the statistically analysed 12 patients were on
prednisone therapy for ulcerative colitis. The control group con-
sisted of 27 age- and sex-matched healthy blood donors. There
were 17 men and 10 women and the mean age was 42 years (range
21 to 64) in the control group. The study was approved by the
local ethics committee and an informed consent was obtained from
each patient.
Operation
All the patients underwent a standard panproctocolectomy opera-
tion during general anaesthesia. The operation involved an ileo-
anal anastomosis with a J-pouch in ten cases and a conventional
ileostomy in five cases. The mean operation time was 200 minutes
(range 160 to 225). The mean blood loss during the operations was
1280 ml (range 350 to 3200). The blood volume was maintained
with infusions of isotonic electrolyte solutions, and packed red
blood cells were given to maintain the blood haemoglobin concen-
tration above 100 g/1. Twelve patients recovered uneventfully and
three patients had postoperative complications as described above.
Blood samples
Blood samples were collected in the morning before the operation
and daily thereafter until the seventh postoperative day. An addi-
tional blood sample was taken at the routine follow-up examination
about three months after the operation. Serum was separated and
stored at -20 °C until assayed. The mass concentrations of group
I phospholipase A2 and group II phospholipase Aa, the catalytic
activity concentration of phospholipase A2 and the mass concentra-
tion of C-reactive protein were measured. The mass concentrations
of group I and group II phospholipases Aa were analysed by time-
resolved fluoroimmunoassays (17, 18), the catalytic activity con-
centration of phospholipase A2 was assayed by using micellar ra-
dioactive phosphatidylcholine as a substrate (19), and the mass
concentration of C-reactive protein by immunoturbidimetry (stan-
dard and antiserum from Orion Diagnostica, Espoo, Finland).
Blood samples of the control group were collected by taking 10 ml
blood from 27 healthy donors during routine blood donations.
Statistical analysis
The results are expressed as mean and standard error of mean
(±SEM) for the 12 patients who recovered uneventfully, and as
case profiles for the three patients with postoperative complica-
tions. The statistical analysis for repeated measurements was car-
ried out using analysis of variance in the SAS system MIXED
procedure (version 6.11). The model is based on the restricted max-
imum likelihood estimation method, one between factor, and un-
structured covariance structure. Contrasts were used to compare
differences between time points. The t-test for independent samples
was used to compare preoperative and late postoperative group II
phospholipase A2 values with the values of the control group.
Results
Figure 1 shows the mean mass concentrations of group
I and group II phospholipases A2, the mean catalytic
activity concentration of phospholipase A2 and the mean
mass concentration of C-reactive protein at consecutive
time points in sera of 12 panproctocolectomy patients.
The mass concentration of group I phospholipase A2
seemed to increase slightly (less than two-fold) from the
first postoperative day on, peaked on the fourth postop-
erative day, and then decreased (fig. 1). The overall
time-related change was not significant (p= 0.100, F=
1.75, DF= 8 and 78). The mass concentration of group
II phospholipase A2 was increased five-fold on the first
postoperative day, and then decreased to almost preoper-
ative levels during days two to five (fig. 1). The overall
time-related change was significant at p < 0.001, F=
3.79, DF= 8 and 77. The difference between preopera-
tive values and values on the first postoperative day was
significant at p < 0.001, F= 18.69, DF= 1 and 77. The
catalytic activity concentration of phospholipase A2 was
doubled on the first postoperative day, and then de-
creased (fig. 1). The overall time-related change was sig-
nificant at p= 0.030, F= 2.28, DF= 8 and 77. The dif-
ference between preoperative values and values on the
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Fig. 1 Mass concentrations of group I phospholipase A2 and
group II phospholipase A.2, the catalytic activity concentration of
phospholipase A.2 and the mass concentration of C-reactive protein
in the sera of 12 consecutive patients undergoing a panproctocolec-
tomy operation for ulcerative colitis (mean ±SEM). Preoperative
samples (0) were taken in the morning before the panproctocolec-
tomy operation, postoperative samples in the following mornings
until the seventh postoperative day and at the follow up examina-
tion three months after the operation.
first postoperative day was significant at p= 0.002, F=
10.65, DF 1 and 77. The mass concentration of C-re-
active protein reached the peak mean value on the se-
cond postoperative day and the pattern of the change
of the mean values resembled that of the mean mass
concentration of group II phospholipase AI (fig. 1). The
overall time-related change of C-reactive protein was
significant at ρ < 0.001, F= 7.90, DF 8 and 79. The
difference between preoperative values and values on the
second postoperative day was significant at ρ < 0.001,
F= 35.79, DF 1 and 79.
The three patients with postoperative complications had
peak values of group II phospholipase AI mass concen-
trations and phospholipase Aa catalytic activity concen-
trations at the time of the respective postoperative com-
plications (fig. 2). The episode of postoperative respira-
tory insufficiency was accompanied by the highest in-
creases in group II phospholipase A2 mass
concentration, phospholipase A2 catalytic activity con-
centration and C-reactive protein mass concentration
(fig. 2).
The concentrations of all the quantities studied were at
relatively low levels preoperatively and essentially sim-
ilar levels were measured at the time of a check-up three
months postoperatively. This was true for all patients
including the three with early postoperative complica-
tions. Both preoperative and late postoperative (three
months) levels of group II phospholipase AI (mean
9.7 μg/l and 12.7 μg/l, respectively) were moderately
increased when compared with the level of a healthy
control group (mean 5.5 μg/l). The differences were sta-
tistically significant (T= 3.4 and T= 4.7, respectively,
DF= 37 and ρ < 0.005 for both comparisons).
Discussion
Experimental models have indicated that secretory phos-
pholipases AI have diverse biological roles in host de-
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Fig. 2 Case profiles of group II phospholipase A.2 mass concen-
trations, the catalytic activity concentrations of phospholipase A.2
and the mass concentrations of C-reactive protein in three patients
with postoperative complications after panproctocolectomy. The
time points are the same as in figure 1. Note the logarithmic scale
of phospholipase AI values. Patient A (—o—) was reoperated for
intestinal obstruction on the seventh day after the panproctocolec-
tomy operation. Patient Β (—D—) had a pneumonia diagnosed by
chest X-ray on the seventh postoperative day. Patient C (-O-)
had an episode of acute respiratory insufficiency and was therefore
admitted to the intensive care unit on the third postoperative day.
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fence, in the generation of lipid mediators and in the am-
plification of inflammatory reactions (12). Intravascular
release and intravenous infusion of phospholipases A2 are
associated with systemic effects such as cardiovascular
collapse and acute lung injury in experimental animals
(20, 21). The mass concentration of group II phospholi-
pase A2 increases in serum in a similar way to that of other
acute phase proteins in a variety of inflammatory diseases
and postoperative states (22-24).
Various human cells and organs, including the small and
large intestine, are capable of synthesising group II
phospholipase A2 (9, 25). Yet, it is not fully established
which organ or cells are responsible for the secretion of
the enzyme into the blood circulation. These (unknown)
cells are of general interest since they might be indi-
rectly responsible for the systemic organ effects of the
enzyme. Earlier studies have shown that a major opera-
tion, even without an inflammatory disease, can elevate
the mass concentration of group II phospholipase Aa in
serum (26—28). In the current study, the mass concen-
tration of group II phospholipase A2 and the catalytic
activity concentration of phospholipase A2 increased
rapidly and temporarily and reached peak levels one day
after the panproctocolectomy operation. The half-life of
group II phospholipase A2 in circulating human blood,
in a situation where the synthesis of the enzyme is insig-
nificant, is not known. Nevertheless, it is known from
experiments with rats that the half-life of intravenously
injected group I and group II phospholipase A2 is 2.85
minutes and less than 30 seconds, respectively (29, 30).
On the other hand, Vadas and co-authors reported that
the estimated half-life of circulating soluble phospholi-
pase A2 in septic shock in man is 32 hours (31). The
latter study was based on measurements from patients
recovering from septic shock and probably represents a
situation where the synthesis and the secretion of the
enzyme into the circulation decrease slowly. This situa-
tion resembles the postoperative state of the present pa-
tients better than the experiments with intravenous injec-
tions of the enzyme preparations (29, 30). Based on the
findings of the earlier animal experiments, we assume
that the effect of possible intraoperative transfer of
group II phospholipase A2 from the large intestine into
the blood circulation on the serum level of the enzyme
is negligible. In the current study, we noted three cases
with postoperative complications in which increases in
the group II phospholipase A2 levels in serum were ob-
served later than in the group with no complications,
and'the peak levels corresponded to the time of the re-
spective complication. Taking these facts together, we
conclude that the rapid postoperative increase in the en-
zyme levels is attributable to significant postoperative
secretion of group II phospholipase A2 from some other
organ than the removed large intestine. In an earlier
study, hepatocytes were proposed as a major source of
circulating group II phospholipase A2 (32).
The results of the current work differ from those of
earlier studies in one interesting detail. Peak values of
group II phospholipase A2 mass concentration were
earlier found to occur typically on the second, third or
fourth postoperative days (24, 26—28, 33), whereas we
demonstrated peak values on the first postoperative day
in patients with ulcerative colitis. This difference may
be explained by the different study group in the current
work in which all the patients had a chronic inflamma-
tory disease and underwent major colonic surgery . The
underlying inflammation may promote a faster response
than in cases without preoperative inflammation.
Furthermore, a surgical procedure on the colon may
cause intraoperative translocation of endotoxin (34, 35),
which is a potent inducer of phospholipase A2 catalytic
activity and group II phospholipase A2 protein synthesis
(36—38). The penetration of endotoxin through the in-
testinal wall is facilitated by mucosal inflammation (39,
40) which may also contribute to the proposed intraoper-
ative translocation of endotoxin in this patient group.
Earlier experimental studies have shown peak levels of
phospholipase A2 activity in the circulation 24 hours af-
ter controlled exposure to endotoxin in humans (37, 38).
Another explanation for the rapid increase in group II
phospholipase A2 is the possible release of synthesised
and stored enzyme due to chronic inflammation. Human
neutrophils have been shown to release presynthesised
group II phospholipase A2 in response to stimulation
(41). However, in a previous immunohistochemical
study of the colonic wall and mesentery for group II
phospholipase A2 at the site of inflammation in ulcera-
tive colitis, we could not detect any immunoreactivity
in inflammatory cells, which were readily visualised in
crypt abscesses and lymph nodes. Neither could we de-
tect group II phospholipase A2 mRNA in the inflamma-
tory cells by in situ hybridisation (9). Taking these facts
together, we assume that inflammatory cells are not the
main source of circulating group II phospholipase A2 in
ulcerative colitis. The surgical trauma caused by a major
abdominal operation most probably induces additional
synthesis of group II phospholipase A2 for systemic re-
lease in most patients, including those with ulcerative
colitis. The observed lack of response on the second to
fourth postoperative days in the current study may be
explained by the corticosteroid therapy which was given
to 11 of the 12 patients analysed. Corticosteroids inhibit
the synthesis of group II phospholipase A2 protein (36)
and down-regulate the phospholipase A2 enzyme activ-
ity (42, 43). The corticosteroid therapy may also explain
why the postoperative increases in group II phospholi-
pase A2 mass concentrations were rather moderate (five-
fold) in the current study compared with earlier studies
(27, 28) in which the postoperative increases were more
than ten-fold. The amplitude of increase in the mass
concentration of group II phospholipase A2 (five-fold)
was greater than the increase of the catalytic activity
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concentration of phospholipase AI (two-fold). This
might be a result of the action of endogenous phospholi-
pase A2 inhibiting factors and (or) medication, which
might inhibit phospholipase AI activity more than the
synthesis of group II phospholipase AI protein. The in-
creases observed in the mass concentration of group II
phospholipase A2 and the catalytic activity concentra-
tion of phospholipase A2 in serum after panproctocolec-
tomy are most probably normal host reactions to a major
abdominal operation, and suggest a role for this enzyme
in the generalised inflammatory reaction. On this basis,
group II phospholipase A.2 can be considered as an acute
phase protein.
The profile of the mean values of the catalytic activity
concentration of phospholipase A.2 follows a pattern that
could be a result of both group I phospholipase AI and
group II phospholipase A2 activity, because the profiles
of the corresponding mass concentrations have peak val-
ues at the same time points as the catalytic activity con-
centration. However, the changes in the catalytic activity
concentration on the fourth postoperative day and the
overall time-related changes of group I phospholipase
A2 mass concentration were not significant (p= 0.130
and p= 0.100 respectively). Thus, the current data do
not indicate a role for group I phospholipase A2 in the
postoperative recovery period in ulcerative colitis.
Comparisons between the preoperative enzyme levels
and those at the follow-up three months later must be
made with considerable caution because of the change
in the medical treatment during that period. Especially
the discontinuation of corticosteroid treatment may alter
the result. We feel that reliable estimates of the late im-
pact of panproctocolectomy on phospholipase A2 en-
zyme levels cannot be based on the results of the current
study. Nevertheless, we have shown that the removal of
the large intestine does not terminate the secretion of
group II phospholipase A2 into the circulation in patients
with ulcerative colitis. We have also shown that these
patients have increased levels of group II phospholipase
A2 in serum preoperatively and postoperatively when
compared with a control group of healthy blood donors.
Conclusion
The catalytic activity concentration of phospholipase A2
and the mass concentration of group II phospholipase
A2 increase rapidly and temporarily after panproctoco-
lectomy in sera of patients with ulcerative colitis. The
observation supports the idea that group II phospholi-
pase A2 is an acute phase protein and indicates that the
large intestine is not the main source of circulating
group II phospholipase A2 in patients with active ulcera-
tive colitis. The results also support the assumption that
the catalytic activity of phospholipase A2 in serum is
attributable to group II phospholipase A2.
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